Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration
Abstract Adjuvants play a crucial role in enhancing vaccine efficacy. Although several adjuvants have been approved, there remains a demand for safer and more effective adjuvants for nasal vaccines. Here, we identified calboxyvinyl polymer (CVP) as a superior mucosal vaccine adjuvant from pharmaceut...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01086-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243728846880768 |
|---|---|
| author | Eita Sasaki Hideki Asanuma Haruka Momose Jun–ichi Maeyama Saya Moriyama Noriyo Nagata Tadaki Suzuki Isao Hamaguchi Hideki Hasegawa Yoshimasa Takahashi |
| author_facet | Eita Sasaki Hideki Asanuma Haruka Momose Jun–ichi Maeyama Saya Moriyama Noriyo Nagata Tadaki Suzuki Isao Hamaguchi Hideki Hasegawa Yoshimasa Takahashi |
| author_sort | Eita Sasaki |
| collection | DOAJ |
| description | Abstract Adjuvants play a crucial role in enhancing vaccine efficacy. Although several adjuvants have been approved, there remains a demand for safer and more effective adjuvants for nasal vaccines. Here, we identified calboxyvinyl polymer (CVP) as a superior mucosal vaccine adjuvant from pharmaceutical base materials using our screening systems; single nasal vaccination of the CVP-combined influenza split vaccine-induced antigen-specific IgA and IgG antibodies and provided protection against lethal influenza virus infection. Furthermore, nasal vaccination with CVP-combined severe acute respiratory syndrome coronavirus 2 antigen protected against the virus and stimulated the production of highly cross-reactive IgG antibodies against variants XBB1.5 and JN.1. Intriguingly, intramuscular vaccination of the CVP-combined vaccine also elicited the production of IgA antibodies in both nasal wash and bronchoalveolar lavage fluid in mice and cynomolgus monkeys. CVP therefore offers superior adjuvanticity to existing adjuvants and is anticipated to be a safe and effective adjuvant for mucosal vaccines. |
| format | Article |
| id | doaj-art-9eb4b59c222f4afd8d42870abbcefeea |
| institution | OA Journals |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-9eb4b59c222f4afd8d42870abbcefeea2025-08-20T01:59:56ZengNature Portfolionpj Vaccines2059-01052025-02-0110111910.1038/s41541-025-01086-0Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administrationEita Sasaki0Hideki Asanuma1Haruka Momose2Jun–ichi Maeyama3Saya Moriyama4Noriyo Nagata5Tadaki Suzuki6Isao Hamaguchi7Hideki Hasegawa8Yoshimasa Takahashi9Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1–23–1 ToyamaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, 4–7–1 GakuenResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, 4–7–1 GakuenResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, 4–7–1 GakuenResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1–23–1 ToyamaDepartment of Pathology, National Institute of Infectious Diseases, 4–7–1 GakuenDepartment of Pathology, National Institute of Infectious Diseases, 4–7–1 GakuenResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, 4–7–1 GakuenCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, 4–7–1 GakuenResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1–23–1 ToyamaAbstract Adjuvants play a crucial role in enhancing vaccine efficacy. Although several adjuvants have been approved, there remains a demand for safer and more effective adjuvants for nasal vaccines. Here, we identified calboxyvinyl polymer (CVP) as a superior mucosal vaccine adjuvant from pharmaceutical base materials using our screening systems; single nasal vaccination of the CVP-combined influenza split vaccine-induced antigen-specific IgA and IgG antibodies and provided protection against lethal influenza virus infection. Furthermore, nasal vaccination with CVP-combined severe acute respiratory syndrome coronavirus 2 antigen protected against the virus and stimulated the production of highly cross-reactive IgG antibodies against variants XBB1.5 and JN.1. Intriguingly, intramuscular vaccination of the CVP-combined vaccine also elicited the production of IgA antibodies in both nasal wash and bronchoalveolar lavage fluid in mice and cynomolgus monkeys. CVP therefore offers superior adjuvanticity to existing adjuvants and is anticipated to be a safe and effective adjuvant for mucosal vaccines.https://doi.org/10.1038/s41541-025-01086-0 |
| spellingShingle | Eita Sasaki Hideki Asanuma Haruka Momose Jun–ichi Maeyama Saya Moriyama Noriyo Nagata Tadaki Suzuki Isao Hamaguchi Hideki Hasegawa Yoshimasa Takahashi Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration npj Vaccines |
| title | Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration |
| title_full | Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration |
| title_fullStr | Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration |
| title_full_unstemmed | Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration |
| title_short | Calboxyvinyl polymer adjuvant enhances respiratory IgA responses through mucosal and systemic administration |
| title_sort | calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration |
| url | https://doi.org/10.1038/s41541-025-01086-0 |
| work_keys_str_mv | AT eitasasaki calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT hidekiasanuma calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT harukamomose calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT junichimaeyama calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT sayamoriyama calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT noriyonagata calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT tadakisuzuki calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT isaohamaguchi calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT hidekihasegawa calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration AT yoshimasatakahashi calboxyvinylpolymeradjuvantenhancesrespiratoryigaresponsesthroughmucosalandsystemicadministration |